I agree that this site is using cookies. You can find further informations
here
.
X
Login
Merkliste (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
zur Desktop-Version
Toggle navigation
Merkliste
1 Ergebnisse
1
Efficacy of lenvatinib combined with sequential transarteri..:
Qing-Yun Xie
;
Lu-Ping Huang
;
Feng-Wei Gao
...
https://www.frontiersin.org/articles/10.3389/fphar.2022.965770/full. , 2022
Link:
https://doi.org/10.3389/fphar.2022.965770
RT Journal T1
Efficacy of lenvatinib combined with sequential transarterial chemoembolization for primary hepatocellular carcinoma and the effects on serum basic fibroblast growth factor and vascular endothelial growth factor
UL https://suche.suub.uni-bremen.de/peid=base-ftdoajarticles:oai:doaj.org_article:4229a3310947479b980426d741b9d58c&Exemplar=1&LAN=DE A1 Qing-Yun Xie A1 Lu-Ping Huang A1 Feng-Wei Gao A1 Da-Qing Liu A1 Xia Wang A1 Kang-Yi Jiang A1 Jie Gong A1 Xin Zhao A1 Ben-Jian Gao A1 Ze-Hua Lei PB Frontiers Media S.A. YR 2022 K1 hepatocellular carcinoma K1 transarterial chemoembolization K1 lenvatinib K1 basic fibroblast growth factor K1 vascular endothelial growth factor K1 Therapeutics. Pharmacology K1 RM1-950 JF https://www.frontiersin.org/articles/10.3389/fphar.2022.965770/full LK http://dx.doi.org/https://doi.org/10.3389/fphar.2022.965770 DO https://doi.org/10.3389/fphar.2022.965770 SF ELIB - SuUB Bremen
Export
RefWorks (nur Desktop-Version!)
Flow
(Zuerst in
Flow
einloggen, dann importieren)